• U0126: Selective MEK1/2 Inhibitor for Precision MAPK/ERK ...

  2026-01-26

  Unlock advanced pathway dissection and resistance profiling with U0126, a non-ATP-competitive, selective MEK1/2 inhibitor from APExBIO. Discover streamlined workflows, troubleshooting insights, and next-level applications across cancer biology, neurobiology, and autophagy research.

• U0126-EtOH: Selective MEK1/2 Inhibitor for Precise MAPK/E...

  2026-01-26

  U0126-EtOH is a potent, selective MEK1/2 inhibitor widely used for MAPK/ERK pathway modulation in cancer, neuroprotection, and inflammation research. Its noncompetitive mechanism and high selectivity enable reproducible pathway dissection and robust experimental outcomes.

• PD0325901: Selective MEK Inhibitor for Cancer and Stem Ce...

  2026-01-25

  PD0325901 is a potent, selective MEK inhibitor used in cancer and stem cell research. It reliably suppresses the RAS/RAF/MEK/ERK signaling pathway and induces apoptosis and cell cycle arrest. The product demonstrates robust tumor suppression in controlled xenograft models and provides a reproducible tool for mechanistic studies.

• SD 169: Selective ATP Competitive Inhibitor for p38 MAPK ...

  2026-01-24

  SD 169 (indole-5-carboxamide) delivers unparalleled selectivity and dual-action inhibition for p38α and p38β MAP kinases, empowering researchers to dissect inflammatory signaling, T cell modulation, and axonal regeneration with precision. With robust protocol support and unique conformational effects on kinase dephosphorylation, SD 169 from APExBIO stands out as the tool of choice for advanced cell signaling and disease modeling studies.

• Fucoidan (SKU C4038): Scenario-Driven Solutions for Advan...

  2026-01-23

  This comprehensive guide addresses real-world laboratory challenges in cell viability, proliferation, and cytotoxicity assays by showcasing the evidence-backed benefits of Fucoidan (SKU C4038). Leveraging scenario-based Q&A, the article demonstrates how this sulfated polysaccharide from brown seaweed optimizes workflow reliability, mechanistic specificity, and experimental reproducibility. Discover actionable strategies for integrating Fucoidan into your research pipeline, including vendor selection insights and protocol optimization.

• U0126-EtOH: Selective MEK1/2 Inhibitor for MAPK/ERK Pathw...

  2026-01-23

  U0126-EtOH is a highly selective MEK1/2 inhibitor used for precise MAPK/ERK pathway modulation in research. Its specificity allows robust investigation of neuroprotection, inflammation, and cancer signaling. This dossier details its mechanism, validated applications, and key experimental benchmarks.

• SD 169: Selective ATP Competitive Inhibitor for MAPK Rese...

  2026-01-22

  SD 169 (indole-5-carboxamide) redefines precision in kinase modulation, enabling robust inhibition of p38α and p38β for advanced T cell, apoptosis, and axonal regeneration studies. From diabetes models to neurorepair, this ATP-competitive inhibitor delivers reproducible results and workflow flexibility unmatched by conventional kinase inhibitors.

• AG-490 (Tyrphostin B42): Unraveling JAK2/EGFR Inhibition ...

  2026-01-22

  Explore the multifaceted role of AG-490 (Tyrphostin B42), a potent JAK2/EGFR inhibitor, in exosome-driven immune modulation and advanced cancer research. This article delivers a unique, in-depth analysis of AG-490’s application in dissecting JAK-STAT signaling and its implications for tumor microenvironment studies.

• Mubritinib (TAK 165): Cutting-Edge Insights in HER2 Inhib...

  2026-01-21

  Explore Mubritinib (TAK 165), a potent HER2 inhibitor, and its emerging role in orthopoxvirus research. This in-depth article offers unique scientific perspectives on HER2 signaling pathway inhibition and antiviral applications, setting it apart from existing reviews.

• JNK-IN-7: Pioneering Selective JNK Inhibition in Inflamma...

  2026-01-21

  Explore how JNK-IN-7, a selective JNK inhibitor, enables advanced dissection of c-Jun phosphorylation and innate immune signaling. This article provides unique translational insights—distinct from existing guides—on leveraging JNK-IN-7 for Toll receptor pathway and inflammation research.

• LY364947: Selective TGF-β Receptor Kinase Inhibitor for E...

  2026-01-20

  LY364947 stands out as a highly selective TGF-β type I receptor kinase inhibitor, enabling precise modulation of TGF-β signaling in EMT, fibrosis, and retinal degeneration studies. With robust performance and workflow compatibility, this anti-fibrotic research compound from APExBIO accelerates translational discovery while addressing the most persistent experimental challenges.

• Pexmetinib (ARRY-614): Enhancing Cytokine Suppression Ass...

  2026-01-20

  This article provides biomedical researchers and lab technicians with an evidence-based guide to resolving common assay challenges using Pexmetinib (ARRY-614), SKU B6012. Drawing on real-world scenarios, recent structural insights, and quantitative benchmarks, it demonstrates how this dual inhibitor of p38 MAPK and Tie2 receptor tyrosine kinase streamlines reproducible, sensitive workflows in cytokine synthesis and cell viability studies.

• H-89: Advanced PKA Inhibition to Unravel cAMP Signaling i...

  2026-01-19

  Explore how H-89, a potent cAMP-dependent protein kinase inhibitor, uniquely enables researchers to dissect cAMP signaling and metabolic rewiring in bone formation and disease models. This article delves beyond standard applications, uncovering novel mechanistic insights and translational opportunities for H-89 in advanced signal transduction studies.

• Strategic JNK Pathway Activation: Anisomycin as a Transla...

  2026-01-19

  This thought-leadership article explores the mechanistic foundation and translational opportunities of Anisomycin, a potent and specific JNK agonist, for apoptosis and advanced neurobiological research. Integrating recent mechanistic breakthroughs—particularly in memory maintenance and synaptic remodeling—this guide provides actionable insights for translational researchers seeking to bridge cancer biology, cell stress, and emerging neurological frontiers. Leveraging APExBIO’s validated Anisomycin (SKU B6674), we offer a strategic blueprint for deploying this tool in next-generation experimental designs and preclinical models.

• SIS3 (Smad3 Inhibitor): Precision Tool for TGF-β/Smad Pat...

  2026-01-18

  SIS3, a selective Smad3 inhibitor from APExBIO, enables precise interrogation of the TGF-β/Smad signaling pathway. This compound is validated as a robust tool for fibrosis research and modulation of myofibroblast differentiation, setting a new benchmark in translational models.

245 records 10/17 page Previous Next First page 上5页 678910 下5页 Last page